Risperidone
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Risperidone |
| DrugBank ID | DB00734 |
| Brand Names (EU) | Okedi |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | manic bipolar affective disorder | 99.98% | DL |
| 2 | autism spectrum disorder | 99.78% | DL |
| 3 | autism susceptibility 1 | 99.77% | DL |
| 4 | gaze palsy, familial horizontal, with progressive scoliosis | 99.76% | DL |
| 5 | asperger syndrome, susceptibility to | 99.74% | DL |
| 6 | amelocerebrohypohidrotic syndrome | 99.69% | DL |
| 7 | Phelan-McDermid syndrome | 99.59% | DL |
| 8 | trichotillomania | 99.51% | DL |
| 9 | major affective disorder | 99.11% | DL |
| 10 | bipolar disorder | 98.89% | DL |
| 11 | Tourette syndrome | 98.76% | DL |
| 12 | intellectual disability | 98.72% | DL |
| 13 | autism, susceptibility to | 98.65% | DL |
| 14 | chromosome 15q11.2 deletion syndrome | 98.59% | DL |
| 15 | 16q24.3 microdeletion syndrome | 98.59% | DL |
| 16 | schizophrenia | 98.55% | DL |
| 17 | occipital pachygyria and polymicrogyria | 98.32% | DL |
| 18 | attention deficit-hyperactivity disorder | 98.26% | DL |
| 19 | distal 17p13.3 microdeletion syndrome | 98.20% | DL |
| 20 | epsilon-trimethyllysine hydroxylase deficiency | 98.14% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.